From the SEC filing from Acadia (my formatting):
In addition, pursuant to the License Agreement, Neuren granted to the Company a worldwide, exclusive license to develop and commercialize any product developed by or on behalf of Neuren or the Company containing a NNZ-2591 compound as an active ingredient (a “NNZ-2591 Product”) for the treatment of Rett syndrome and Fragile X syndrome (the “Acadia NNZ-2591 Field”). Neuren may conduct development and commercialization of NNZ-2591 outside of the Acadia NNZ-2591 Field.
- Forums
- ASX - By Stock
- Ann: Q2 2023 quarterly activity and cash flow report
From the SEC filing from Acadia (my formatting):In addition,...
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$20.21 |
Change
-1.060(4.98%) |
Mkt cap ! $2.583B |
Open | High | Low | Value | Volume |
$20.98 | $21.06 | $20.14 | $6.308M | 308.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3926 | $20.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.21 | 388 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3926 | 20.190 |
3 | 2210 | 20.180 |
3 | 1953 | 20.170 |
1 | 1058 | 20.150 |
3 | 2758 | 20.100 |
Price($) | Vol. | No. |
---|---|---|
20.220 | 2110 | 2 |
20.280 | 1037 | 2 |
20.300 | 5554 | 4 |
20.370 | 1107 | 2 |
20.390 | 3000 | 1 |
Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online